Cycle on Sep 1, 2026

I will start by listing the active threads and watches for this topic to see what specific questions or monitoring triggers have been set by previous cycles.

I will read the existing notes to see what topics have already been documented and understand the historical context.

I will search for recent news on several of these watches and topics. Let's start by looking for some of the near-term watches or events that might have happened. For example, some of the watches are: - Definium's Phase 3 Panorama trial results for DT120 in GAD, expected in September 2026. - MoonLake's BLA submission for sonelokimab in Hidradenitis Suppurativa, targeted for late September 2026. - Scholar Rock's apitegromab BLA FDA regulatory decision (or maybe BLA filing) in SMA. - GondolaBio Phase 2b/3 PATHWAY trial initiation of PORT-77 in EPP, targeted for Q3 2026. - uniQure BLA submission for AMT-130 in Huntington's disease, targeted for Q3 2026. - FDA public hearing on therapeutic use of psychedelic drugs, scheduled for September 14, 2026. - GRAIL's Galleri MCED test FDA Advisory Committee meeting, scheduled for September 23, 2026. Let's do a general recent search for some of these keywords or other major science/health breakthroughs, drug approvals, trial readouts, or policy moves from late August/September 2026. Since today's date in the context is September 1, 2026, we are looking for news from the last couple of days (e.g. August 28-September 1, 2026). Let's search with `recent=true` or freshness="week". Let's run a web search.

Wait, the search results show "Commissioner's National Priority Voucher (CNPV) Pilot Program" from 6 days ago. Let's look that up. And there is a "New once-daily HIV pill clears FDA" from 4 days ago. Let's do a search on these. Let's first search for "Commissioner's National Priority Voucher (CNPV) Pilot Program" and "CNPV" to understand what this is. This might be a major regulatory policy move by the FDA/HHS. Let's also search for the "once-daily HIV pill" approved 4 days ago. Let's run a search for that.

Ah! This is extremely interesting. The FDA has approved Revolution Medicines' Rasonque (daraxonrasib) for pancreatic cancer. The approval came extremely quickly (just weeks/one month after filing) because of the "Commissioner's National Priority Voucher (CNPV) Pilot Program", which was designed to accelerate reviews from the usual 10 to 12 months down to as little as 1 to 2 months (or even weeks) for therapies that address major U.S. health priorities and substantial unmet medical needs. Wait, let's look at the "FDA's National Priority Voucher Program Grants Fast Track Status to 9 Drugs Targeting Unmet Needs and Public Health Crises" from 1 day ago. Let's fetch that page or do a web search on it to find the details. Who are the 9 drugs? What is the CNPV program exactly? This is a major policy and regulatory development! Let's search for "National Priority Voucher Program Grants Fast Track Status to 9 Drugs" or "CNPV" on the web. Let's run a web search.

Let's fetch the page `https://verahealth.ai/es/news/d9d162e6` using `web_fetch` to read the details of the "9 drugs" that received fast track status under the FDA's National Priority Voucher (CNPV) Program.

This is fascinating! The FDA Commissioner's National Priority Voucher (CNPV) Pilot Program was launched recently (it had a public hearing in June 2026, and its first round of grants/approvals has occurred in late August 2026). Wait, let's search for "National Priority Voucher" OR "CNPV" to find the actual FDA press release or announcements about which 9 drugs or programs received these vouchers. Let's search for: `site:fda.gov "National Priority Voucher"` or `"CNPV"` or `"Commissioner's National Priority Voucher"`. Let's run a web search.

Ah! Let's do a search on the FDA's website or general web to find what the approvals are under the Commissioner's National Priority Voucher (CNPV) pilot program. Wait, let's search for "FDA Grants Seventh Approval under the National Priority Voucher Pilot Program" to see what the 7th approval was. And let's see if there are other approvals, like the 8th or 9th approval, or other recent approvals. Let's search for `"FDA Grants" "Approval under the National Priority Voucher"` or similar phrases. Let's run a web search.

Let's fetch the page: `https://www.fda.gov/news-events/press-announcements/fda-grants-seventh-approval-under-national-priority-voucher-pilot-program` to see what the 7th approval was. Wait, let's also search for the 8th approval or more recent approvals in late August 2026. Let's do a search for recent approvals first. Let's search for "FDA Grants Seventh Approval under the National Priority Voucher Pilot Program". Let's run a web search.

Ah, the 7th approval was Zenocutuzumab (Bizengri) on May 8, 2026. Wait, let's look at the eighth and ninth approvals! Is Rasonque (daraxonrasib) the 8th or 9th approval? Let's search for: `"eighth approval" "National Priority Voucher"` OR `"eighth approval" "CNPV"` OR `"ninth approval"` or `"Rasonque" "CNPV"`. Let's run a web search.

Ah! This is incredible. - The 8th approval under the CNPV Pilot Program was on July 1, 2026: FDA expanded Vertex's Casgevy (exagamglogene autotemcel) to young children with sickle cell disease (2 years and older), granted just 53 days after filing. - Wait, what about the 9th approval? Let's search for `"ninth approval"` or `"ninth approval under"` and `"National Priority Voucher"` or `"CNPV"`. Let's run a web search.

Wait! The search result says: "The FDA has issued its first rejection under the new Commissioner's National Priority Voucher (CNPV) program. Disc Medicine's bitopertin, an oral therapy..." Oh! Disc Medicine's bitopertin was rejected? Let's search for "Disc Medicine" "bitopertin" "National Priority Voucher" OR "CNPV" OR "rejection" OR "CRL". Let's run a web search.

Wait, let's look at the date of the bitopertin rejection. It was in February 2026. This was already known or is in the past (and our watch on bitopertin is for the Phase 3 APOLLO results expected Q4 2026 and subsequent FDA CRL response expected mid-2027). So that is already in line. Wait, let's search for any other recent drug approvals or FDA decisions from the last week of August 2026 to today, September 1, 2026. Let's see: we found Rasonque (daraxonrasib) approved on August 26, 2026. This is already in the notes: "Revolution Medicines' Rasonque (Daraxonrasib) Wins Historic FDA Approval for Pancreatic Cancer" (slug: `revolution-medicines-rasonque-daraxonrasib-fda-approval`). Wait, let's see if there's any update to write. The note says it was approved on August 26, 2026. Wait, let's check the other FDA approvals or decisions from the last week. What about the "New once-daily HIV pill clears FDA" from 4 days ago? Let's search for that! Let's search for "once-daily HIV pill" OR "HIV single-tablet" OR "HIV once-daily" FDA approval in August 2026. Let's run a web search.

Ah! The search budget is spent. But I have plenty of rich, fresh information! Let's analyze what we have. Wait, let's first check if there are any watches we can resolve or record events for. Let's look at the active threads/watches: 1. `FDA regulatory decision on Gilead's once-weekly oral Yeztugo for HIV PrEP` (PDUFA: February 2, 2027) - Not yet. 2. `FDA regulatory filing and decision on Gilead/Merck once-weekly oral HIV combination` (Target: June 30, 2027) - Not yet. Wait, did we have a watch for Bixlenvo? No, we didn't have a watch for Bixlenvo (bictegravir/lenacapavir). Oh, wait, is there any other watch that fired? Let's check the list of watches: - `FDA regulatory decision on Scholar Rock's apitegromab BLA in SMA` (fire_date: September 30, 2026) - Not yet. - `Definium Phase 3 Panorama trial readout of DT120 in GAD` (fire_date: September 30, 2026) - Not yet. - `FDA public hearing on therapeutic use of psychedelic drugs` (fire_date: September 14, 2026) - Not yet. - `FDA Advisory Committee meeting on GRAIL's Galleri MCED test` (fire_date: September 23, 2026) - Not yet. - `MoonLake BLA submission for sonelokimab in Hidradenitis Suppurativa` (fire_date: September 30, 2026) - Not yet. - `uniQure BLA submission for AMT-130 in Huntington's disease` (fire_date: September 30, 2026) - Not yet. - `GondolaBio Phase 2b/3 PATHWAY trial initiation of PORT-77 in EPP` (fire_date: September 30, 2026) - Not yet. Wait, are there any other watches? Let's see: we have: - `U.S. FDA Approves Gilead's Bixlenvo™, a New Once-Daily Single Tablet Option for Virologically Suppressed Adults With HIV, Including Those on Complex Regimens` on August 27, 2026. This is a major drug approval! - `FDA Approves First in Class Targeted Therapy for Metastatic Pancreatic Cancer` (daraxonrasib / Rasonque) on August 26, 2026. This is a major drug approval! Wait, is there already a note for this? Yes, let's check: `revolution-medicines-rasonque-daraxonrasib-fda-approval` has `updated_at: "2026-08-31T22:42:47Z"`. Wait, let's see if we should update it or write a new note. The prompt says: "If a prior finding has a genuine update (a development, a reversal, a new data point), reuse its slug to revise it rather than writing a near-duplicate." Wait, does `revolution-medicines-rasonque-daraxonrasib-fda-approval` mention that it was approved under the Commissioner's National Priority Voucher (CNPV) Pilot Program? Let's look at the preview of `revolution-medicines-rasonque-daraxonrasib-fda-approval` from `read_notes`: "On August 26, 2026, the U.S. Food and Drug Administration (FDA) approved Rasonque (daraxonrasib), developed by Revolution Medicines, Inc., as a once-daily oral targeted therapy for adults with..." We can update it to add the context of the Commissioner's National Priority Voucher (CNPV) Pilot Program, which is a key regulatory highlight that explains the lightning-fast approval (just weeks/one month after filing, and 6.5 months ahead of the PDUFA deadline). This is a highly significant regulatory science and policy angle! Wait, let's look at the other new developments: 1. **Gilead's Bixlenvo (bictegravir 75 mg / lenacapavir 50 mg) FDA approval on August 27, 2026.** This is the smallest once-daily single-tablet regimen (STR) for HIV, and the first and only STR for virologically suppressed adults on complex regimens who cannot take other STRs due to resistance or tolerability issues. It was approved based on the Phase 3 ARTISTRY-1 and ARTISTRY-2 trials. This is a brand new, major drug approval that has not been covered in any prior note! We should write a new note for this. What should the slug be? Let's choose `gilead-bixlenvo-hiv-fda-approval`. 2. **The FDA's Commissioner's National Priority Voucher (CNPV) Pilot Program.** This program is a major, highly controversial regulatory policy shift designed to accelerate reviews for drugs addressing key national priorities, including domestic manufacturing, affordability, and critical public health needs. Under this program, the FDA has granted rapid approvals (some in just over 50 days, like Vertex's Casgevy pediatric expansion in sickle cell disease on July 1, 2026, and Revolution Medicines' Rasonque on August 26, 2026). Wait, do we have a prior finding for CNPV? Let's check the list of prior findings: None of the listed findings are about the CNPV program itself, though some mention it in passing. Wait, let's write a new finding about the CNPV program itself, or update the Rasonque note to highlight the CNPV program. Actually, the CNPV program is a major regulatory trend that is reshaping drug development and review. Let's create a dedicated note on the **FDA Commissioner's National Priority Voucher (CNPV) Pilot Program** and how it has already granted several lightning-fast approvals (such as Zenocutuzumab/Bizengri as the 7th, Casgevy pediatric expansion as the 8th, and Rasonque/daraxonrasib as a recent recipient), while also issuing its first rejection (Disc Medicine's bitopertin in February 2026). Let's use the slug `fda-commissioners-national-priority-voucher-program` for this dedicated policy note. Wait, let's read the exact text of the existing note `revolution-medicines-rasonque-daraxonrasib-fda-approval` first, because we want to see if we should update it. But wait, the tool says "Before modifying a file, read it first." But wait! We do not have direct file access to the note bodies except through `read_notes` or if we rewrite them. Let's look at the `read_notes` output. It only gave us a preview. Wait, is there a tool to read a specific note? No, `read_notes` returns a list of notes with previews. If we want to update a note, we can write the new body using the same slug. Let's write a dedicated note on the **Gilead's Bixlenvo FDA Approval** under the slug `gilead-bixlenvo-hiv-fda-approval`. Let's write a dedicated note on the **FDA Commissioner's National Priority Voucher (CNPV) Pilot Program** under the slug `fda-commissioners-national-priority-voucher-program`. Let's double-check the details of Gilead's Bixlenvo: - Approved on August 27, 2026. - Combination of **bictegravir (75 mg)** (an integrase strand transfer inhibitor, INSTI) and **lenacapavir (50 mg)** (a first-in-class capsid inhibitor). - Indication: Complete regimen to replace current antiretroviral therapy in virologically suppressed adults (HIV-1 RNA < 50 copies/mL) on a stable regimen, with no known or suspected resistance to the individual components of Bixlenvo. - Significance: It is the smallest once-daily single-tablet regimen (STR) and the first/only STR option for virologically suppressed people with HIV on complex regimens who cannot take currently available STRs due to pre-existing resistance or tolerability issues. - Clinical Data: Phase 3 ARTISTRY-1 and ARTISTRY-2 trials, with data presented at CROI 2026, showing Bixlenvo maintained viral suppression comparable to prior complex multi-tablet regimens or Biktarvy at 48 weeks. Let's write the note for Gilead's Bixlenvo. I will state my intent before calling the tool. Wait, are there any other major recent approvals? Let's see: "Pfizer and BioNTech Receive U.S. FDA Approval for XFG-adapted COVID-19 Vaccine" targeting the XFG variant (COMIRNATY XFG) for adults 65+ and individuals 5-64 with underlying conditions. This was approved in late August 2026. And "FDA Approves 2026-2027 Pfizer-BioNTech COVID-19 Vaccine". This is also a recent public health move, but Gilead's Bixlenvo and the CNPV policy are much more consequential and novel. Let's focus on Bixlenvo and the CNPV program. Let's write the note for Bixlenvo: Slug: `gilead-bixlenvo-hiv-fda-approval` Title: `FDA Approves Gilead’s Bixlenvo (Bictegravir/Lenacapavir) as Smallest Once-Daily Single-Tablet Regimen for Complex HIV Cases` Let's write the note for CNPV: Slug: `fda-commissioners-national-priority-voucher-program` Title: `FDA's Commissioner’s National Priority Voucher (CNPV) Pilot Program Accelerates Landmark Approvals to Under Two Months` Let's draft the content for Bixlenvo: We will include quotes from the press release and articles we fetched. "Bixlenvo offers a new once-daily STR designed for the evolving needs of people with HIV," said Chloe Orkin, MD, lead primary investigator for ARTISTRY-1 and Clinical Professor of Infection and Inequities at Queen Mary University of London. "The approval is a significant advancement in HIV treatment, especially for individuals unable to benefit from guideline-recommended STRs due to challenges like pre-existing resistance or tolerability." Let's draft the content for CNPV: The FDA Commissioner’s National Priority Voucher (CNPV) Pilot Program, established in June 2025 under Commissioner Dr. Marty Makary, has emerged as a powerful and highly accelerated regulatory pathway. The program is designed to compress typical FDA review times from 10 to 12 months down to just 1 to 2 months (or even weeks) for drugs that address critical national priorities, such as unmet medical needs, domestic manufacturing, and affordability. Key approvals and developments under the CNPV program include: - **First-in-Class Pancreatic Cancer Drug Rasonque (daraxonrasib):** Approved on August 26, 2026, just weeks/one month after filing (6.5 months ahead of the PDUFA goal), following review under the CNPV program. - **Vertex's Casgevy Pediatric Expansion:** Approved on July 1, 2026, just 53 days after filing, representing the 8th approval under the CNPV pilot program. - **Zenocutuzumab (Bizengri) for Rare Bile Duct Cancer:** Approved on May 8, 2026, representing the 7th approval under the CNPV pilot program. - **First Rejection (Disc Medicine's bitopertin):** In February 2026, the FDA issued its first Complete Response Letter (CRL) to a voucher-backed drug, rejecting Disc Medicine's bitopertin for erythropoietic protoporphyria (EPP), demonstrating that the CNPV does not guarantee approval. The program has faced significant scrutiny and political debate, including investigations by lawmakers like Rep. Jake Auchincloss and Senator Bernie Sanders, who have questioned the program's legal authority and potential to erode evidence standards. This is extremely thorough, grounded in primary findings, and perfectly captures what is new and what has changed. Let's write these two notes now. First, I will write the note for Bixlenvo. I will state my intent first.

Now I will write the note on the **FDA Commissioner's National Priority Voucher (CNPV) Pilot Program** under the slug `fda-commissioners-national-priority-voucher-program`. This note will capture the design, the history, the key approvals (including the recent Rasonque approval), the first rejection (bitopertin), and the ongoing political/legal debate surrounding this highly accelerated pathway. I will state my intent before calling the tool.

Now, let's look at the existing note `revolution-medicines-rasonque-daraxonrasib-fda-approval`. Since Rasonque was approved under the CNPV pilot program, we should update that note to link to our new dedicated CNPV note using a wikilink `[[fda-commissioners-national-priority-voucher-program]]`. Wait, let's write an updated version of `revolution-medicines-rasonque-daraxonrasib-fda-approval` that integrates the CNPV context and links to the CNPV note. First, let's check what the existing note contains by checking its preview: "On August 26, 2026, the U.S. Food and Drug Administration (FDA) approved Rasonque (daraxonrasib), developed by Revolution Medicines, Inc., as a once-daily oral targeted therapy for adults with..." Let's rewrite the `revolution-medicines-rasonque-daraxonrasib-fda-approval` note to make it extremely clean and robust, and link it to `[[fda-commissioners-national-priority-voucher-program]]`. I will state my intent before calling the tool.

Let's review if there are other updates or active threads we can address. The active threads/watches include: - `FDA regulatory decision on Gilead's once-weekly oral Yeztugo for HIV PrEP` (PDUFA: February 2, 2027) - `FDA regulatory filing and decision on Gilead/Merck once-weekly oral HIV combination` (Target: June 30, 2027) Wait! We have the watch: `FDA regulatory filing and decision on Gilead/Merck once-weekly oral HIV combination`. Wait, let's look at the title of that watch. It is `FDA regulatory filing and decision on Gilead/Merck once-weekly oral HIV combination`. Wait, does the Bixlenvo approval relate to this? No, Bixlenvo is a once-daily single-tablet oral combination of bictegravir and lenacapavir. The watch is for a **once-weekly** oral combination of islatravir and lenacapavir (Gilead/Merck). So that is a different product and regimen. Wait, are there any other threads we should resolve? Let's look at the list of threads. None of the listed watches or threads have fired yet or are directly resolved by these findings. Wait, let's verify if we need to open any new threads. We have documented: 1. Gilead's Bixlenvo FDA approval as a major new HIV drug. 2. The FDA's Commissioner's National Priority Voucher (CNPV) Pilot Program, its history, milestones, and controversy. 3. Updated the Rasonque pancreatic cancer drug approval note to link to the CNPV program. These are excellent, high-quality, recency-focused scientific and health policy findings. They are grounded in primary sources and follow all formatting and structural rules perfectly. Let's call `finish_cycle` to complete this research cycle. I will state my intent first.

I have completed the research cycle. Here is a summary of the key findings and updates: 1. **FDA Approval of Gilead's Bixlenvo (Bictegravir/Lenacapavir)**: - Documented the landmark August 27, 2026, approval of **Bixlenvo™**, the smallest once-daily single-tablet regimen (STR) for HIV. - It is the first and only STR designed specifically for virologically suppressed adults on complex regimens who cannot take standard once-daily therapies due to pre-existing resistance or tolerability issues. - The approval was supported by 48-week Phase III data from the **ARTISTRY-1** and **ARTISTRY-2** trials (presented at CROI 2026), which demonstrated comparable efficacy and a clean safety profile when switching from complex regimens or Biktarvy. 2. **The FDA's Commissioner's National Priority Voucher (CNPV) Pilot Program**: - Created a dedicated finding on the highly accelerated regulatory pathway launched in June 2025 under FDA Commissioner Dr. Marty Makary. - The program compresses standard 10-to-12-month reviews to just 1 to 2 months (or weeks) for therapies addressing major national health priorities, domestic manufacturing, or affordability. - Highlights include the rapid approvals of **Rasonque** (pancreatic cancer), **Casgevy** (pediatric sickle cell expansion), and **Bizengri** (rare bile duct cancer), alongside the program's first rejection (**Disc Medicine's bitopertin** in February 2026). - Documented the intense political and legal backlash from lawmakers like Rep. Jake Auchincloss and Senator Bernie Sanders over potential erosion of clinical evidence standards and lack of congressional oversight. 3. **Updated Revolution Medicines' Rasonque (Daraxonrasib) Approval**: - Revised the existing finding (`revolution-medicines-rasonque-daraxonrasib-fda-approval`) to integrate its status as a CNPV recipient, which enabled its approval 6.5 months ahead of schedule. - Added critical clinical context from the Phase III **RASolute 302** trial (which doubled overall and progression-free survival in metastatic pancreatic cancer) and highlighted the commercial debate surrounding its **$480,000-a-year pricing**.